DUBLIN--(BUSINESS WIRE)--The "Investigation Report on China's Rabeprazole Market 2021-2025" report has been added to ResearchAndMarkets.com's offering.

Rabeprazole is a kind of proton pump inhibitor (PPI) gastric acid inhibitor. It is used for the treatment of gastroesophageal reflux disease and maintenance treatment after recovery.

It is also suitable for the treatment of duodenal ulcers and Zollinger-Ellison syndrome. Rabeprazole's product PARIET, developed by Eisai Pharmaceutical Co., Ltd. of Japan, was approved in China in 2000. As of the end of 2020, there are more than 10 manufacturers in the Chinese Rabeprazole market, of which Jiangsu Aosaikang Pharmaceutical Co., Ltd. accounts for the largest market share.

According to the market research, the sales value of Rabeprazole in the Chinese market increased year by year from 2016 to 2019. Due to the impact of the COVID-19 epidemic on the overall medical diagnosis and treatment services, the sales value decreased to CNY1.334 billion in 2020, with a year-on-year decrease of 11.01%. The CAGR of the sales value of Rabeprazole from 2016 to 2020 is 9.66% in China.

The analyst predicts that the sales of Rabeprazole will have a restorative growth from 2021 to 2025 with the effective alleviation of the Covid-19 epidemic. At the same time, only Rabeprazole injections among the six PPI injections listed in China are not listed in the national medical insurance catalog as of the first half of 2021.

It may enter medical insurance in the future, prompting sales to continue to increase. In addition, Rabeprazole has no obvious individual differences. Rabeprazole has stabler efficacy and has less interaction with other drugs compared with similar drugs,. Based on these advantages, it is expected that the sales of Rabeprazole in the Chinese market will continue to rise from 2021 to 2025.

Topics Covered:

• The impact of COVID-19 on China's Rabeprazole market
• Sales value of China's Rabeprazole 2016-2020
• Competitive landscape of China's Rabeprazole market
• Prices of Rabeprazole in China
• Prices of Rabeprazole in China by regions and manufacturers
• Analysis of factors affecting the development of China's Rabeprazole market
• Prospect of China's Rabeprazole market from 2021 to 2025

Key Topics Covered:

1 Relevant Concept of Rabeprazole

1.1 Indications for Rabeprazole

1.2 Development of Rabeprazole in China

1.3 Governmental Approval of Rabeprazole in China

1.4 The Impact of COVID-19 on Rabeprazole sales in China

2 Sales of Rabeprazole in China, 2016-2020

2.1 Sales Value of Rabeprazole

2.1.1 Overall Sales Value

2.1.2 Sales Value by Region

2.2 Sales Volume of Rabeprazole

2.2.1 Overall Sales Volume

2.2.2 Sales Volume by Region

2.3 Sales of Rabeprazole by Dosage Form in China, 2016-2020

2.3.1 Injection

2.3.2 Tablets

2.3.3 Enteric-coated Tablets

2.3.4 Enteric-coated Capsules

3 Analysis of Major Rabeprazole Manufacturers in China in 2020

3.1 Analysis of Market Share of Major Rabeprazole Manufacturers

3.1.1 Investigation on Market Share by Sales Value

3.1.2 Investigation on Market Share by Sales volume

3.2 Jiangsu Aosaikang Pharmaceutical Co.,Ltd.

3.2.1 Enterprise Profile

3.2.2 Sales of Aojiaming (Jiangsu Aosaikang Pharmaceutical Co., Ltd.'s Rabeprazole) in China

3.3 Nanjing Chang'ao Pharmaceutical Co., Ltd.

3.3.1 Enterprise Profile

3.3.2 Sales of Aoboping (Nanjing Chang'ao Pharmaceutical Co., Ltd.'s Rabeprazole) in China

3.4 Jichuan Pharmaceutical Group Co., Ltd.

3.4.1 Enterprise Profile

3.4.2 Sales of JUMPCAN (Jichuan Pharmaceutical Group Co., Ltd.'s Rabeprazole) in China

3.5 Eisai (China) Pharmaceutical Co., Ltd.

3.5.1 Enterprise Profile

3.5.2 Sales of PARIET (Eisai (China) Pharmaceutical Co., Ltd.'s Rabeprazole) in China

3.6 Shandong Luoxin Pharmaceutical Group Co., Ltd.

3.6.1 Enterprise Profile

3.6.2 Sales of Kapeilai (Shandong Luoxin Pharmaceutical Group Co., Ltd.'s Rabeprazole) in China

4 Prices of Rabeprazole for Different Manufacturers in China, 2020-2021

4.1 Jiangsu Aosaikang Pharmaceutical Co., Ltd. (Aojiaming)

4.2 Nanjing Chang'ao Pharmaceutical Co., Ltd. (Aoboping)

4.3 Jichuan Pharmaceutical Group Co., Ltd. (JUMPCAN)

4.4 Eisai (China) Pharmaceutical Co., Ltd. (PARIET)

4.5 Shandong Luoxin Pharmaceutical Group Co., Ltd. (Kapeilai)

5 Prospect of Chinese Rabeprazole Market, 2021-2025

5.1 Influential Factors of Chinese Rabeprazole Market Development

5.1.1 The Impact of COVID-19 on Chinese Rabeprazole Market

5.1.2 Market Drivers and Opportunities

5.1.3 Market Threats and Challenges

5.2 Forecast on Market Size

5.3 Forecast on Market Trend

For more information about this report visit https://www.researchandmarkets.com/r/rlrpiu

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900